Meta-analysis of trials comparing gemcitabine and pegylated liposomal doxorubicin for treatment in women with progressive or recurrent ovarian cancer
X Liu, L Ma, J Tian, K Yang - Clinical Oncology and Cancer Research, 2009 - Springer
Objective To evaluate the efficacy and adverse effects of gemcitabine versus pegylated
liposomal doxorubicin in patients with progressive or recurrent ovarian cancer. Methods We …
liposomal doxorubicin in patients with progressive or recurrent ovarian cancer. Methods We …
[PDF][PDF] Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
G Ferrandina, M Ludovisi, D Lorusso… - Journal of Clinical …, 2008 - academia.edu
Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive
or Recurrent Ovarian Cancer Page 1 Phase III Trial of Gemcitabine Compared With Pegylated …
or Recurrent Ovarian Cancer Page 1 Phase III Trial of Gemcitabine Compared With Pegylated …
A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC)
G Ferrandina, D Lorusso, S Pignata, E Breda… - Journal of Clinical …, 2007 - ascopubs.org
LBA5506 Background: This multi-center Phase III study was designed to compare the
efficacy and safety of PLD vs GEM in ovarian cancer (OC) patients relapsing within 12 …
efficacy and safety of PLD vs GEM in ovarian cancer (OC) patients relapsing within 12 …
[CITATION][C] Pegylated liposomal doxorubicin vs gemcitabine for ovarian cancer
DG Mutch - Inpharma, 2007 - Springer
In their randomised trial, 195 such patients received IV gemcitabine 1000 mg/m2 on days 1
and 8, every 21 days (n= 99) or IV pegylated liposomal doxorubicin 50 mg/m2 on day 1 …
and 8, every 21 days (n= 99) or IV pegylated liposomal doxorubicin 50 mg/m2 on day 1 …
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens …
Y Takahashi, Y Takei, S Machida… - Journal of Obstetrics …, 2021 - Wiley Online Library
Aim Pegylated liposomal doxorubicin (PLD) is one of the second‐line chemotherapy
regimens for platinum‐resistant recurrent ovarian cancer, but in clinical practice, it is also …
regimens for platinum‐resistant recurrent ovarian cancer, but in clinical practice, it is also …
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
Background Both gemcitabine and pegylated liposomal doxorubicin (PLD) are
antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer …
antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer …
[PDF][PDF] Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line …
E Bayram, G Khatib, U Kuçukgoz-Gulec… - European Review for …, 2023 - researchgate.net
OBJECTIVE: In this retrospective study, we compared the effectiveness and reliability of the
third-line chemotherapies gemcitabine and liposomal doxorubicin, in patients with platinum …
third-line chemotherapies gemcitabine and liposomal doxorubicin, in patients with platinum …
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
MR Mirza, B Lund, JC Lindegaard, N Keldsen… - Gynecologic …, 2010 - Elsevier
OBJECTIVE: Treatment of epithelial ovarian cancer patients relapsing with a short treatment-
free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the …
free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the …
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib …
G Crespo, M Sierra, R Losa, JP Berros… - International Journal of …, 2011 - ijgc.bmj.com
Introduction Pegylated liposomal doxorubicin (PLD) is currently the reference treatment for
platinum-resistant ovarian cancer. The combination of PLD and gemcitabine and the …
platinum-resistant ovarian cancer. The combination of PLD and gemcitabine and the …
Re:“Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival”
M Markman - Gynecologic oncology, 2006 - gynecologiconcology-online.net
In their recent report of a phase 2 study of the combination of gemcitabine (GEM) and
liposomal doxorubicin (PLD) bin the salvage treatment of ovarian cancerQ, Ferrandina et al …
liposomal doxorubicin (PLD) bin the salvage treatment of ovarian cancerQ, Ferrandina et al …